These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32163506)

  • 1. Differential effects of Δ9-tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model.
    Seillier A; Martinez AA; Giuffrida A
    PLoS One; 2020; 15(3):e0230238. PubMed ID: 32163506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats.
    Seillier A; Advani T; Cassano T; Hensler JG; Giuffrida A
    Int J Neuropsychopharmacol; 2010 Apr; 13(3):373-86. PubMed ID: 19607756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia.
    Aguilar DD; Giuffrida A; Lodge DJ
    J Psychopharmacol; 2016 Feb; 30(2):169-81. PubMed ID: 26510449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Δ9-tetrahydrocannabinol (Δ9-THC) administration after neonatal exposure to phencyclidine potentiates schizophrenia-related behavioral phenotypes in mice.
    Rodríguez G; Neugebauer NM; Yao KL; Meltzer HY; Csernansky JG; Dong H
    Pharmacol Biochem Behav; 2017 Aug; 159():6-11. PubMed ID: 28648819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB₁ receptors: implications for schizophrenia.
    Seillier A; Martinez AA; Giuffrida A
    Neuropsychopharmacology; 2013 Aug; 38(9):1816-24. PubMed ID: 23563893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia.
    Vigano D; Guidali C; Petrosino S; Realini N; Rubino T; Di Marzo V; Parolaro D
    Int J Neuropsychopharmacol; 2009 Jun; 12(5):599-614. PubMed ID: 18789179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing endocannabinoid levels in the ventral pallidum restore aberrant dopamine neuron activity in the subchronic PCP rodent model of schizophrenia.
    Aguilar DD; Chen L; Lodge DJ
    Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of fatty acid amide hydrolase reverses aberrant prefrontal gamma oscillations in the sub-chronic PCP model for schizophrenia.
    Seillier A
    Exp Brain Res; 2024 May; 242(5):1149-1160. PubMed ID: 38489023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delta9-tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors.
    Hejazi N; Zhou C; Oz M; Sun H; Ye JH; Zhang L
    Mol Pharmacol; 2006 Mar; 69(3):991-7. PubMed ID: 16332990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of chronic delta9-tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment.
    Wu X; French ED
    Neuropharmacology; 2000 Jan; 39(3):391-8. PubMed ID: 10698005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of social cognition in the sub-chronic PCP rat model of schizophrenia: Possible involvement of the endocannabinoid system.
    Seillier A; Giuffrida A
    Eur Neuropsychopharmacol; 2016 Feb; 26(2):298-309. PubMed ID: 26706691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics.
    Fernández-Ruiz JJ; Muñoz RM; Romero J; Villanua MA; Makriyannis A; Ramos JA
    Biochem Pharmacol; 1997 Jun; 53(12):1919-27. PubMed ID: 9256167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801.
    Seillier A; Giuffrida A
    Behav Brain Res; 2009 Dec; 204(2):410-5. PubMed ID: 19716985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral Characterization of the Effects of Cannabis Smoke and Anandamide in Rats.
    Bruijnzeel AW; Qi X; Guzhva LV; Wall S; Deng JV; Gold MS; Febo M; Setlow B
    PLoS One; 2016; 11(4):e0153327. PubMed ID: 27065006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phencyclidine affects firing activity of ventral tegmental area neurons that are related to reward and social behaviors in rats.
    Katayama T; Okamoto M; Suzuki Y; Hoshino KY; Jodo E
    Neuroscience; 2013 Jun; 240():336-48. PubMed ID: 23458711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct neuronal activation patterns are associated with PCP-induced social withdrawal and its reversal by the endocannabinoid-enhancing drug URB597.
    Matricon J; Seillier A; Giuffrida A
    Neurosci Res; 2016 Sep; 110():49-58. PubMed ID: 27091613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Delta9-tetrahydrocannabinol during adolescence increases sensitivity to subsequent cannabinoid effects in delayed nonmatch-to-position in rats.
    Wiley JL; Burston JJ
    Pharmacol Biochem Behav; 2010 Feb; 94(4):516-23. PubMed ID: 19941884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic phencyclidine treatment induces long-lasting glutamatergic activation of VTA dopamine neurons.
    Uramura K; Maejima Y; Shimomura K; Santoso P; Katsuda S; Kobayashi D; Jodo E; Kodaira M; Otgon-Uul Z; Yang Y; Sakuma K; Takigawa M; Hazama A; Yada T
    Neurosci Lett; 2014 Apr; 564():72-7. PubMed ID: 24525246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function.
    Romero J; de Miguel R; García-Palomero E; Fernández-Ruiz JJ; Ramos JA
    Brain Res; 1995 Oct; 694(1-2):223-32. PubMed ID: 8974649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine.
    Guidali C; Viganò D; Petrosino S; Zamberletti E; Realini N; Binelli G; Rubino T; Di Marzo V; Parolaro D
    Int J Neuropsychopharmacol; 2011 Feb; 14(1):17-28. PubMed ID: 20196921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.